A retrospective cohort study to evaluate the effectiveness and safety profile of occipital nerve blocks in the treatment of migraine during pregnancy
Abstract
Nearly 12% of Americans experience migraine, with 75% of that group represented by women aged 15–55 years, notably including peak childbearing years. This presents a therapeutic dilemma for pregnant patients, given that most medications for migraine range from unknown teratogenicity in human pregnancies, at best, to known teratogenicity, severely limiting their utility. However, migraine causes significant disability and impairment in the lives of pregnant patients, necessitating treatment. We conducted a retrospective chart review and phone survey to evaluate the safety profile and effectiveness of bilateral occipital nerve blocks to treat migraine during pregnancy.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.